Sahajanand Medical Technologies IPO: OFS structure, dates, business profile, financials, KPIs and key risks

Sahajanand Medical Technologies Limited, an R&D-led medical device manufacturer focused on high-risk cardiovascular implants and consumables, is set to launch a mainboard IPO that is structured as an Offer for Sale (OFS). The issue opens on 15 Oct 2026 and closes on 19 Oct 2026, with allotment scheduled for 21 Oct 2026 and listing slated for 23 Oct 2026. Based on the disclosed objects of the offer, the IPO comprises an OFS of 13,822,116 equity shares (face value ₹1 each), representing 13.60% of the company’s pre-offer equity share capital, with no fresh issue indicated in the available slice. The price band, lot size and the rupee-denominated issue size are not yet available in the supplied details.

Because this is an OFS, any proceeds from the share sale (once priced) go to the selling shareholders, while the company’s stated object also includes achieving the benefits of listing its equity shares on the stock exchanges.

What the company does: high-risk cardiovascular devices across two therapy areas

Sahajanand Medical Technologies Limited operates as an integrated manufacturer and seller of medical devices used in cardiovascular interventions, with an emphasis on products that typically require stringent regulatory and clinical pathways.

Its portfolio spans two core segments. The Vascular Intervention segment includes coronary stents, percutaneous transluminal coronary angioplasty (PTCA) balloons and drug-coated balloons. The Structural Heart segment includes transcatheter aortic valve implantation (TAVI) valves and occluders.

The company manufactures through integrated facilities in India and Thailand and sells across a broad international footprint. It positions products with clinical evidence and global regulatory clearances, and cites brand examples such as Supraflex Cruz (drug-eluting stent), Hydra (TAVI) and Cocoon (occluders). In an implantable, high-risk device business, execution depends heavily on consistent manufacturing quality, traceability and ongoing compliance across multiple markets.

IPO structure and stated objectives: OFS-only offer and listing benefits

In the provided disclosures, the Sahajanand Medical Technologies IPO is presented as an OFS. The stated objects of the offer are (i) to carry out the OFS of 13,822,116 equity shares by the selling shareholders (aggregating up to an amount yet to be specified in the documents), and (ii) to achieve the benefits of listing the equity shares on the stock exchanges.

No fresh issue component is indicated in the supplied snapshot. This matters for how investors interpret capital flows: a fresh issue would bring primary capital into the company, while an OFS primarily enables shareholding rebalancing and public market participation, alongside the corporate benefits typically associated with listing.

On category reservations, the disclosed framework assigns 50% of the net offer to Qualified Institutional Buyers (QIBs), 15% to Non-Institutional Investors (NIIs) and 35% to Retail Individual Investors (RIIs). Within the QIB portion, the anchor allocation is indicated as up to 60% of the QIB portion, with a 33.33% reservation for domestic mutual funds within the anchor book. An employee reservation of ₹0.25 crore is also shown in the provided details.

As of the snapshot date (12 Oct 2026), the issue is marked as upcoming; category-wise bidding data is expected to populate after the subscription window opens on 15 Oct 2026.

Corporate milestones: investment, clinical trial progress and acquisitions

The company’s disclosed milestones point to a mix of funding, clinical development and inorganic expansion over the past decade.

In 2016, Samara Capital Markets Holding Limited invested about ₹400.00 million by subscribing to shares and also bought shares from existing shareholders for about ₹400.00 million.

In 2017, Sahajanand Medical Technologies completed enrolment of 1,435 patients for the TALENT clinical trial evaluating a sirolimus-eluting coronary stent. For a device-led business, the completion of patient enrolment is a notable marker within clinical evidence generation.

In 2019, the company acquired Imex Salud S.L. to establish direct operations in Spain, indicating a move toward direct market presence in at least one European geography.

In 2020, it acquired Vascular Concepts Limited and Vascular Innovations, which the company states enabled entry into structural heart products such as occluders and TAVI.

In 2021, the company converted from a private limited company to a public limited company and was renamed Sahajanand Medical Technologies Limited.

Financial trajectory: revenue, profitability and asset base movement

Across FY2024 to FY2026, the company reported rising revenue and total assets, alongside a shift from a reported loss in FY2024 to reported profitability in FY2025 and FY2026.

Revenue increased from ₹901.60 crore in FY2024 to ₹1,024.88 crore in FY2025 and ₹1,210.50 crore in FY2026. Profit after tax (PAT) moved from a loss of ₹7.35 crore in FY2024 to a profit of ₹25.15 crore in FY2025 and ₹69.08 crore in FY2026. The reported PAT margin correspondingly moved from negative in FY2024 to positive in FY2025 and improved further in FY2026.

The balance sheet expanded over the same period, with total assets rising from ₹970.58 crore in FY2024 to ₹1,094.90 crore in FY2025 and ₹1,276.43 crore in FY2026. These figures provide the primary context available in the supplied materials for interpreting scale and recent financial direction ahead of the IPO.

KPIs, leverage and what is available (and not available) on valuation

The supplied KPI set provides operating and return metrics, but it does not provide the missing inputs needed to discuss offer-price-based valuation.

On profitability and operating profile, the company reports an EBITDA margin of 13.81% and a reported PAT margin of 4.29%. It reports earnings per share (EPS) of ₹6.80. Return ratios disclosed include return on equity (ROE) of 2.07%, return on capital employed (ROCE) of 3.16% and return on net worth (RoNW) of 2.31%. The disclosed debt-to-equity ratio is 0.33.

However, price-based valuation discussion typically relies on an announced price band (or offer price) and the relevant share count to compute meaningful multiples and market capitalisation at the offer price. In the supplied snapshot, the price band and lot size are not available, and the pre-IPO price-to-earnings and price-to-book fields are shown as 0, which does not provide a usable valuation reference.

The grey market premium (GMP) observations provided in this snapshot show ₹30 on 11 Oct 2026, ₹40 later on 11 Oct 2026, and ₹40 on 12 Oct 2026 (with a referenced issue price of ₹344 in that observation). GMP is an unofficial market indicator and can change; these dated observations are best read as a time-stamped sentiment data point rather than as a listing outcome.

Key risks in the disclosed framing and monitoring points to track

The disclosed risk framing highlights factors commonly associated with regulated, high-risk medical device businesses selling across multiple jurisdictions.

Regulatory approvals and renewals can be slow or withdrawn, which can affect the pace of product launches and ongoing sales and may increase testing costs if additional requirements arise. Manufacturing issues or low capacity utilisation can raise unit costs, delay deliveries and affect relationships with hospitals and regulators, particularly in implantable devices where reliability, documentation and quality systems are central. The company also flags a governance and compliance-related risk: missing historical corporate records could trigger regulatory questions later, potentially resulting in legal costs and management distraction.

Monitoring points for investors and market participants as the offer progresses and after listing can be stated clearly from these disclosures. Track regulatory approval and renewal outcomes across key markets where the company sells cardiovascular devices. Track disclosures that signal manufacturing continuity, quality outcomes and capacity utilisation, given the operational impact these can have. Track clinical evidence disclosures and portfolio developments in vascular intervention and structural heart categories. Track any disclosures relating to historical records, compliance processes or related legal matters that could influence timelines and management focus.

Complete numeric snapshot

IPO terms and schedule

Key performance indicators and valuation

Category reservations and anchor allocation

Subscription status (12 Oct 2026)

Grey market premium (GMP) trend

GMP is an unofficial market indicator and can change; these are dated snapshot observations, not a listing forecast.